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BACKGROUND: Stroke is a morbid and potentially mortal complication 
among patients hospitalized with acute medical illness. The potential 
of extended-duration thromboprophylaxis with the factor Xa inhibitor 
betrixaban to reduce the risk of stroke compared with standard-dose 
enoxaparin in this population was assessed in this retrospective APEX trial 
substudy (Acute Medically Ill Venous Thromboembolism Prevention With 
Extended Duration Betrixaban).
METHODS: Hospitalized acutely medically ill subjects (n=7513) were 
randomized in a double-dummy double-blind fashion to either extended-
duration oral betrixaban (80 mg once daily for 35–42 days) or standard-
dose subcutaneous enoxaparin (40 mg once daily for 10±4 days) for 
venous thromboprophylaxis. Stroke events were adjudicated by an 
independent, blinded event adjudication committee.
RESULTS: The mean age of study participants was 76 years; 45% were 
male; 13% had had a stroke; and 45% had congestive heart failure. 
There were fewer all-cause strokes (0.54% versus 0.97%; relative risk 
[RR]=0.56; 95% confidence interval, 0.32–0.96; P=0.032; adjusted 
RR=0.43%; number needed to treat=233) and ischemic strokes (0.48% 
versus 0.91%; RR=0.53; 95% confidence interval, 0.30–0.94; P=0.026; 
adjusted RR=0.43%; number needed to treat=233) among patients treated 
with betrixaban versus enoxaparin through 77 days of follow-up. Among 
high-risk subjects, those with congestive heart failure or ischemic stroke 
as their index event, betrixaban reduced the risk of all-cause stroke (0.72% 
versus 1.48%; RR=0.49; 95% confidence interval, 0.26–0.90; P=0.019; 
adjusted RR=0.76%; number needed to treat=132) and ischemic stroke 
(0.63% versus 1.38%; RR=0.45; 95% confidence interval, 0.24–0.87; 
P=0.014; adjusted RR=0.75%; number needed to treat=134) compared 
with enoxaparin.
CONCLUSIONS: Among hospitalized medically ill patients, extended-
duration betrixaban significantly reduced all-cause stroke and ischemic 
stroke through 77 days of follow-up
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Stroke is a leading cause of morbidity and mortality worldwide.1 In-hospital stroke complicates 0.04% to 0.06% of all hospitalizations and constitutes 
2.2% to 15.2% of all strokes.2–9 Stroke among patients 
hospitalized for an acute medical illness portends a less 
favorable outcome compared with community-onset 
stroke.6 However, little is known about the effective-
ness of novel oral anticoagulants for stroke prevention 
in this context. The APEX trial substudy (Acute Medically 
Ill Venous Thromboembolism Prevention With Extended 
Duration Betrixaban) evaluated the safety and efficacy 
of an extended duration of thromboprophylaxis with the 
oral anticoagulant betrixaban in the prevention of venous 
thromboembolism.10 The aim of this retrospective sub-
study was to evaluate the efficacy of extended-duration 
betrixaban versus standard thromboprophylactic enoxa-
parin in the reduction of stroke among hospitalized medi-
cally ill patients.
METHODS
The APEX trial substudy design has been described in detail 
elsewhere.11 This study was approved by an institutional review 
committee, and all subjects provided informed consent. The 
APEX trial substudy was a randomized, double-blind, placebo-
controlled, clinical trial that randomized acutely medically ill 
hospitalized subjects at elevated risk for venous thromboem-
bolism to either standard-dose subcutaneous enoxaparin (40 
mg once daily for 10±4 days) or extended-duration oral betrix-
aban (80 mg once daily for 35–42 days). The dose of study 
drug was adjusted among subjects with renal insufficiency and 
a creatinine clearance <30 mL/min (both the enoxaparin and 
betrixaban doses were halved) and subjects receiving concom-
itant strong P-glycoprotein inhibitors (only the betrixaban dose 
was halved). The primary efficacy outcome for this substudy 
was the occurrence of all-cause stroke through 77 days of 
follow-up (last visit at up to 47 days of exposure plus 30 days 
after discontinuation to capture any rebound events following 
drug discontinuation).
A blinded, independent clinical events committee adjudi-
cated all events of stroke and transient ischemic attack (TIA). 
Standardized definitions for stroke and related end-point 
events are as follows12: Stroke was defined as an acute neu-
rological vascular event with focal neurological signs lasting 
>24 hours with or without evidence of intracranial hemor-
rhage. If the acute neurological event represented a worsen-
ing of a previous deficit, it must have either persisted for >1 
week or persisted for >24 hours and been accompanied by 
an appropriate new computed tomography or magnetic reso-
nance imaging finding.
All-cause stroke was further subclassified as ischemic, 
hemorrhagic, or of unknown cause on the basis of head imag-
ing or autopsy findings. An ischemic stroke was defined as 
an acute neurological vascular event with focal neurological 
signs lasting >24 hours without evidence of primary intracra-
nial hemorrhage. Neuroimaging may have been normal in the 
early hours after the event, or a brain computed tomography 
may have demonstrated a hypodense region that corresponds 
to an arterial territory. When neurological symptoms were 
present for <24 hours because of successful treatment with 
intravenous tissue-type plasminogen activator or intra-arterial 
therapy, the event was classified as an ischemic stroke even 
in the absence of neuroimaging evidence of ischemic stroke. 
Hemorrhagic transformation on a delayed or follow-up scan 
was classified as part of the index ischemic stroke episode, 
not as a separate event. All mechanistic subtypes of ischemic 
stroke were included such as those due to large-artery (extra-
cranial and intracranial) atherosclerosis, lacunar stroke, cryp-
togenic stroke, and ischemic stroke of other undetermined or 
unusual cause.
Hemorrhagic stroke was defined as an acute neurological 
vascular event with focal neurological signs lasting >24 hours 
or sudden severe headache and meningeal signs and evidence 
of intracranial hemorrhage by neuroimaging or autopsy. The 
hemorrhagic stroke subtypes include intracerebral hemor-
rhage, subarachnoid hemorrhage, and intraventricular hemor-
rhage. Intracranial bleeding of traumatic or presumed traumatic 
origin such as subdural hemorrhage and epidural hemorrhage 
was not included in this definition. Stroke of uncertain type was 
defined as an acute neurological vascular event that fulfills the 
definition of stroke with focal neurological signs lasting >24 
hours or sudden severe headache followed rapidly by coma 
but without neuroimaging or autopsy data to classify as either 
an ischemic or a hemorrhagic stroke. Sudden unexplained 
death without a preceding headache to suggest subarachnoid 
hemorrhage was not included in this definition.
TIA was defined as a transient episode of neurological 
dysfunction (<24 hours) caused by focal brain, spinal cord, or 
retinal ischemia without acute infarction. A stroke rather than a 
TIA was diagnosed even if the symptoms lasted <24 hours if 
there were neuroimaging findings consistent with infarction or 
intracranial bleeding.
Statistical Analysis
All efficacy outcomes were analyzed with the actual dose 
received (including 40 versus 80 mg betrixaban) in the modi-
fied intent-to-treat population, which as a safety population 
includes subjects who received at least 1 dose of study drug. 
The risk of stroke was compared between treatment arms 
with stratification by dosing strategy with the Cochran-Mantel-
Haenszel statistics used to determine significance.
Clinical Perspective
What Is New?
• Among hospitalized medically ill patients, extended-
duration betrixaban significantly reduced all-cause 
stroke and ischemic stroke compared with standard-
of-care enoxaparin through 77 days of follow-up.
What Are the Clinical Implications?
• Extended-duration thromboprophylaxis with an 
experimental oral factor Xa inhibitor may reduce 
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To identify the high-risk subset in the hospitalized medi-
cally ill population, univariate and multivariate logistic regres-
sion analyses were performed. Individuals with any of the 
identified risk factors were defined as high-risk subjects. 
The adjusted stroke risk between treatment groups was cal-
culated by controlling for these covariates. The efficacy of 
betrixaban against enoxaparin was assessed in this high-risk 
subset and among subjects with atrial fibrillation. In addi-
tion, the time to ischemic stroke among high-risk subjects 
receiving betrixaban versus enoxaparin was analyzed with 
the use of the Cox proportional hazards model. All analyses 




The mean age of study participants was 76 years; 45% 
were male; 13% had had a stroke; and 45% had conges-
tive heart failure.10 The patient characteristics of the 2 
groups were quite similar with the only difference be-
tween the 2 groups being a mild imbalance in the inci-
dence of a history of stroke (12.5% [469 of 3759] for 
betrixaban versus 14.0% [527 of 3754] for enoxaparin; 
P=0.046).10 Among the modified intent-to-treat popula-
tion, 19.4% received an adjusted lower dose of study 
medication (19.4% [730 of 3759] versus 19.3% [725 
of 3754]; P=0.91). The use of antiplatelet agent and 
statin was generally well balanced between the 2 groups 
(P=0.70 and P=0.07) and does not modify the treat-
ment effect on stroke (Pinteraction=0.28 and Pinteraction=0.23; 
Table I in the online-only Data Supplement).
Efficacy Outcomes
All-cause stroke was reduced among subjects treated 
with extended-duration betrixaban versus enoxaparin 
(0.54% [20 of 3716] versus 0.97% [36 of 3716]; rela-
tive risk [RR]=0.56; 95% confidence interval [CI], 0.32–
0.96; P=0.032; adjusted RR=0.76%; number needed 
to treat=132), as was ischemic stroke (0.48% [18 of 
3716] versus 0.91% [34 of 3716]; RR=0.53; 95% CI, 
0.30–0.94; P=0.026; adjusted RR=0.43%; number 
needed to treat=233; Table 1). The composite end point 
of all-cause stroke and TIA was also reduced among sub-
jects treated with extended-duration betrixaban versus 
enoxaparin (0.65% [24 of 3716] versus 1.10% [41 of 
3716]; RR=0.59; 95% CI, 0.35–0.97; P=0.034; adjust-
ed RR=0.45%; number needed to treat=223; Table 1). 
There was no significant difference in the proportion of 
patients between treatment groups across the modi-
fied Rankin Scale score (Table II in the online-only Data 
Supplement).
Efficacy similar to that of the entire study population 
was observed among subjects who received the full 80-
mg dose of extended-duration betrixaban but not the 
reduced 40-mg dose (Tables 2 and 3). The reduction in 
all-cause stroke was driven predominantly by a reduc-
tion in ischemic stroke because the risk of hemorrhagic 
stroke was similar.
Among hospitalized medically ill patients, 2 risk 
factors were associated with all-cause stroke through 
the end of study at 77 days: ischemic stroke as the 
index event (odds ratio=4.12; 95% CI, 2.36–7.19; 
P<0.0001) and history of congestive heart failure 
(odds ratio=1.93; 95% CI, 1.10–3.40; P=0.022). In 
the multivariate model, both ischemic stroke (odds ra-
tio=4.93; 95% CI, 2.78–8.73; P<0.001) and conges-
tive heart failure (odds ratio=2.45; 95% CI, 1.38–4.36; 
P=0.002) were independently associated with the out-
come (Table 4). Accordingly, hospitalized medically ill 
patients with either congestive heart failure or ischemic 
stroke as the index event were considered high-risk 
subjects in the study.
Among the high-risk subjects, all-cause stroke was 
significantly reduced in those treated with extended-
duration betrixaban versus enoxaparin (0.72% [15 of 
2075] versus 1.48% [31 of 2095]; RR=0.49; 95% CI, 
0.26–0.90; P=0.019), as was ischemic stroke (0.63% 
[13 of 2075] versus 1.38% [29 of 2095]; RR=0.45; 





(n=3716), n (%) RR (95% CI) P Value
All-cause stroke 20 (0.54) 36 (0.97) 0.56 (0.32–0.96) 0.032*
  Ischemic 18 (0.48) 34 (0.91) 0.53 (0.30–0.94) 0.026*
  Hemorrhagic 1 (0.03) 1 (0.03) 1.00 (0.06–15.98) 1.00
  Uncertain type 1 (0.03) 1 (0.03) 1.00 (0.06–15.98) 1.00
TIA 4 (0.11) 5 (0.13) 0.80 (0.22–2.98) 0.74
All-cause stroke or TIA 24 (0.65) 41 (1.10) 0.59 (0.35–0.97) 0.034*
CI indicates confidence interval; RR, relative risk; and TIA, transient ischemic attack. The modified intent-to-treat population includes all 
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95% CI, 0.24–0.87; P=0.014; Table 5). The reduction 
in ischemic stroke began during the period of parenteral 
therapy and continued to widen throughout the period 
of active therapy (Figure). There was no evidence of re-
bound after discontinuation of betrixaban at day 35 to 
42 (Figure). A significant reduction in the composite of 
all-cause stroke and TIA was also observed among high-
risk subjects treated with extended-duration betrixaban 
versus enoxaparin (0.87% [18 of 2075] versus 1.58% 
[33 of 2095]; RR=0.55; 95% CI, 0.31–0.69; P=0.038; 
Table 5). However, a similar reduction in stroke events 
was observed when a history of atrial fibrillation was add-
ed to ischemic stroke or congestive heart failure as the 
index event, although the number of additional events 
was quite small (Table 6).
DISCUSSION
Among acutely medically ill subjects, the administra-
tion of betrixaban was associated with a reduction in 
the risk of all-cause stroke or TIA. The reduction in all-
cause stroke was driven predominantly by a reduction in 
ischemic stroke. Other factor Xa and IIa inhibitors have 
been used to reduce the risk of cardioembolic stroke 
in subjects with atrial fibrillation. However, the reduction 
in ischemic stroke in the present study was notable in 
those subjects with congestive heart failure or ischemic 
stroke as the index event in the absence of atrial fibrilla-
tion. There were few strokes among subjects with atrial 
fibrillation in the present study, so this retrospective 
study was not adequately powered to assess the benefit 
of betrixaban in this context. Despite this reduction in 
ischemic stroke, betrixaban was not associated with an 
increased risk of major bleeding (0.7% versus 0.6%; RR, 
1.19; 95% CI, 0.67–2.12; P=0.55).10 There was, how-
ever, like all factor Xa inhibitors, a greater rate of major 
or clinically relevant nonmajor bleeds in the betrixaban 
group versus the enoxaparin group (3.1% versus 1.6%; 
RR, 1.97; 95% CI, 1.44–2.68; P=0.03).10
The hospitalized medically ill population is a novel 
population to target for stroke reduction. The stroke pre-
vention guidelines for patients with atrial fibrillation, after 
myocardial infarction, and with stroke may not be that 
relevant to the medically ill population. Although the rates 
of all-cause stroke appear to be low in the study (0.54% 
versus 0.95%), it must be remembered that these were 
77-day crude event rates. On an annualized basis, this 
medically ill population had a potentially higher rate of 





(n=2991), n (%) RR (95% CI) P Value
All-cause stroke 14 (0.47) 30 (1.00) 0.47 (0.25–0.88) 0.016*
  Ischemic 13 (0.44) 28 (0.94) 0.47 (0.24–0.90) 0.019*
  Hemorrhagic 0 (0.00) 1 (0.03) … 0.32
  Uncertain type 1 (0.03) 1 (0.03) 1.00 (0.06–16.01) 1.00
TIA 3 (0.10) 5 (0.17) 0.60 (0.14– 2.51) 0.48
All-cause stroke or TIA 17 (0.57) 35 (1.17) 0.49 (0.27–0.87) 0.012*
CI indicates confidence interval; RR, relative risk; and TIA, transient ischemic attack. Note: The modified intent-to-treat population 
includes all subjects who received at least 1 dose of study drug. The analysis was conducted with actual treatment. The P values were 
calculated with the Cochran-Mantel-Haenszel method.
*Significant.





(n=725), n (%) RR (95% CI) P Value
All-cause stroke 6 (0.82) 6 (0.83) 0.99 (0.32–3.07) 0.99
  Ischemic 5 (0.68) 6 (0.83) 0.83 (0.25–2.70) 0.75
  Hemorrhagic 1 (0.14) 0 (0.00) … 0.32
  Uncertain type 0 (0.00) 0 (0.00) … …
TIA 1 (0.14) 0 (0.00) … 0.32
All-cause stroke or TIA 7 (0.96) 6 (0.83) 1.16 (0.39–3.43) 0.79
CI indicates confidence interval; RR, relative risk; and TIA, transient ischemic attack. The modified intent-to-treat population includes 
all subjects who received at least 1 dose of study drug. The analysis was conducted with actual treatment. The P values were calculated 
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stroke (2.55% versus 4.59%) than that observed in the 
atrial fibrillation population (ROCKET AF [An Efficacy 
and Safety Study of Rivaroxaban With Warfarin for the 
Prevention of Stroke and Non-Central Nervous System 
Systemic Embolism in Patients With Non-Valvular Atrial 
Fibrillation], 2.1% versus 2.4%; ARISTOTLE [Apixaban 
for the Prevention of Stroke in Subjects With Atrial Fibril-
lation], 1.3% versus 1.6%; RE-LY [Randomized Evalua-
tion of Long-Term Anticoagulation Therapy], 1.5% versus 
1.1% versus 1.7%).13–15 Consideration may be given to 
prophylactic strategies such as those described here to 
reduce the risk of stroke in this at-risk population.
Betrixaban has a 20-hour pharmacodynamic half-
life, and this minimizes peak drug concentrations and 
increases drug concentration troughs, thereby reducing 
the peak-to-trough ratio.16 This narrow range of variabil-
ity between peak and trough levels may explain in part 
the benefit in reducing stroke observed in the study. 
With reduced peak drug concentrations, there may be 
a lower risk of hemorrhagic complications, and with in-
creased trough concentrations, there may be a lower 
risk of thrombotic complications. Betrixaban also has a 
very low renal clearance, unlike enoxaparin, which may 
likewise explain, at least in part, the improved outcomes 
in this frail population with impaired creatinine clearance.
The dosing strategy in the APEX trial substudy was 
prespecified, and patients were stratified accordingly at 
randomization. A reduced dosage of betrixaban (load-
ing dose of 80 mg followed by maintenance dose of 
40 mg daily) was administered to subjects with severe 
renal insufficiency or receiving concomitant strong P-gly-
coprotein inhibitors. The full 80-mg dose of betrixaban 
(n=2986) was associated with a significant reduction 
in all-cause stroke or ischemic stroke compared with 
enoxaparin. The lack of superiority of the 40-mg dose 
(n=730) against enoxaparin suggests that the dosage 
Table 4. Multivariate Analysis of Treatment Effect on All-Cause Stroke Among Subjects With Either Congestive 







(95% CI) P Value
RR
(95% CI) P Value
Treatment 20/3716 (0.54)* 36/3716 (0.97)† 0.56 (0.32–0.96) 0.036‡ 0.78 (0.64–0.94) 0.032‡
Ischemic stroke as index 
event
19/837 (2.27) 37/6595 (0.56) 4.93 (2.78–8.73) <0.001‡ 4.05 (2.34–7.00) <0.001‡
History of CHF 38/3887 (0.98) 18/3545 (0.51) 2.45 (1.38–4.36) 0.002‡ 1.93 (1.10–3.37) 0.019‡
CHF indicates congestive heart failure; CI, confidence interval; and RR, relative risk. The modified intent-to-treat population includes all subjects 
who received at least 1 dose of study drug. The analysis was conducted with actual treatment. The reference groups in the model are as follows: 
treatment=enoxaparin/placebo, ischemic stroke as index event=no, and history of CHF=no.
*Event rate is shown for subjects treated with betrixaban.
†Event rate is shown for subjects treated with enoxaparin.
‡Significant.
Figure. Time to ischemic stroke 
among subjects with congestive 
heart failure or ischemic stroke 
as index event. 
The modified intent-to-treat population 
includes all subjects who received 
at least 1 dose of study drug. The 
analysis was conducted using actual 
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may have been excessively reduced for stroke prophy-
laxis in the hospitalized medically ill population.
Congestive heart failure and previous ischemic stroke 
were associated with an ≈2-fold and 4-fold increased risk 
for all-cause stroke among the study population of hos-
pitalized patients. Unless a right-to-left shunt is present, 
venous thromboembolic disease should not cause an ar-
terial stroke. In congestive heart failure, there is a poten-
tial for apical thrombus that can cause embolic stroke, 
whereas in prior recent stroke, there is potentially a ni-
dus of thrombus formation in the cerebral circulation that 
can be a risk factor for recurrent stroke.
It is difficult to ascertain whether the strokes in the 
present study were cardioembolic. Ejection fraction is an 
independent risk factor for stroke among subjects with 
ventricular dysfunction.17 Among subjects with conges-
tive heart failure as their index event, it was not known 
if they had preserved ejection fractions or reduced ejec-
tion fractions because the ejection fraction was not 
recorded. Likewise, echocardiographic data pertaining 
to the presence or absence of clot were not collected 
during this trial. Finally, it is possible that subjects who 
experienced stroke had undiagnosed or nonreported 
atrial fibrillation, left ventricular thrombus, valvulopathy, 
or structural heart diseases such as patent foramen 
ovale that were not assessed and predisposed them to 
paradoxical embolism.
Ventricular dysfunction and a history of stroke are not 
the only conditions associated with an elevated risk of 
stroke18; infection and inflammation are also associated 
with a greater risk of stroke.17,19,20 Similar to venous 
thromboembolism, it is possible that hospitalization and 
the associated stress response predispose medically ill 
patients with preexisting cardiovascular risk factors to 
stroke. Hospitalized patients are more likely to develop 
increases in their catecholamines, transient or sustained 
atrial fibrillation, dehydration, and an increased prothrom-
botic state, which may increase their risk for stroke. In 
addition, subjects with hospitalization-associated venous 
thromboembolism are at risk for paradoxical embolism 
in the presence of structural heart diseases such as pat-
ent foramen ovale.
Table 5. Rate of Stroke or TIA Among Subjects With Either Congestive Heart Failure or Ischemic 





(n=2095), n (%) RR (95% CI) P Value
All-cause stroke 15 (0.72) 31 (1.48) 0.49 (0.26–0.90) 0.019*
  Ischemic 13 (0.63) 29 (1.38) 0.45 (0.24–0.87) 0.014*
  Hemorrhagic 1 (0.05) 1 (0.05) 1.01 (0.06–16.13) 0.99
  Uncertain type 1 (0.05) 1 (0.05) 1.01 (0.06–16.13) 0.99
TIA 3 (0.14) 2 (0.10) 1.51 (0.25–9.05) 0.65
All-cause stroke or TIA 18 (0.87) 33 (1.58) 0.55 (0.31–0.97) 0.038*
CI indicates confidence interval; RR, relative risk; and TIA, transient ischemic attack. The modified intent-to-treat population includes 
all subjects who received at least 1 dose of study drug. The analysis was conducted with actual treatment. The P values were calculated 
with the Cochran-Mantel-Haenszel method.
*Significant.
Table 6. Rate of Stroke or TIA Among Subjects With Congestive Heart Failure or Ischemic Stroke as 





(n=2219), n (%) RR (95% CI) P Value
All-cause stroke 15 (0.69) 32 (1.44) 0.48 (0.26–0.88) 0.015*
  Ischemic 13 (0.59) 30 (1.35) 0.44 (0.23–0.84) 0.011*
  Hemorrhagic 1 (0.05) 1 (0.05) 1.02 (0.06–16.22) 0.99
  Uncertain type 1 (0.05) 1 (0.05) 1.02 (0.06–16.22) 0.99
TIA 3 (0.14) 2 (0.09) 1.52 (0.25–9.10) 0.64
All-cause stroke or TIA 18 (0.82) 34 (1.53) 0.54 (0.30–0.95) 0.029*
CI indicates confidence interval; RR, relative risk; and TIA, transient ischemic attack. The modified intent-to-treat population includes all 
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LIMITATIONS
This analysis was retrospective, and no adjustment was 
made for multiple comparisons. The stroke rate was 
modest in the study. It could be argued that the reduc-
tion in stroke was due to play of chance. However, the 
association of prior stroke and congestive heart failure 
with recurrent stroke and the fact that these subjects 
sustained the greatest event reduction support the bio-
logical plausibility of the observation. The fact there was 
a dose-dependent response with efficacy observed at 
the 80-mg dose and not the 40-mg dose adds to the bio-
logical plausibility of the observation and indicates that 
the 40-mg dose of betrixaban may have been excessive-
ly reduced in patients with severe renal insufficiency and 
those receiving concomitant strong P-glycoprotein inhibi-
tors. Given the smaller sample size of the 40-mg dose 
group, it also may have been relatively underpowered to 
ascertain a difference in event rates.
Although the event rates were low during this period 
of follow-up, they are much higher when conveyed on 
an annualized basis. The ability of betrixaban to reduce 
the risk of stroke over a longer period of time is not 
known.
CONCLUSIONS
Among hospitalized medically ill patients, extended-dura-
tion betrixaban significantly reduced all-cause stroke and 
ischemic stroke compared with standard-of-care enoxa-
parin through 77 days.
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